Odunsi, Kunle

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer

Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 7,945

Tumor-infiltrating NY-ESO-1–specific CD8 + T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer

Matsuzaki, J., Gnjatic, S., Mhawech-Fauceglia, P., Beck, A., Miller, A., Tsuji, T., Eppolito, C., Qian, F., Lele, S., Shrikant, P., et al. (2010) · Proceedings of the National Academy of Sciences

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 859

The mTOR Kinase Determines Effector versus Memory CD8+ T Cell Fate by Regulating the Expression of Transcription Factors T-bet and Eomesodermin

Rao, R. R., Li, Q., Odunsi, K., & Shrikant, P. A. (2010) · Immunity

T-cell and B-cell ImmunologyImmunotherapy and Immune Responses

Cited by 656

Association of Type and Location of BRCA1 and BRCA2 Mutations With Risk of Breast and Ovarian Cancer

Rebbeck, T. R., Mitra, N., Wan, F., Sinilnikova, O. M., Healey, S., McGuffog, L., Mazoyer, S., Chenevix-Trench, G., Easton, D. F., Antoniou, A. C., et al. (2015) · JAMA

BRCA gene mutations in cancerMultiple and Secondary Primary Cancers

Cited by 521

Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints

Mikucki, M. E., Fisher, D. T., Matsuzaki, J., Skitzki, J. J., Gaulin, N. B., Muhitch, J. B., Ku, A. W., Frelinger, J. G., Odunsi, K., Gajewski, T. F., et al. (2015) · Nature Communications

Chemokine receptors and signalingCancer Immunotherapy and Biomarkers

Cited by 512

Generation and regulation of human CD4 + IL-17-producing T cells in ovarian cancer

Miyahara, Y., Odunsi, K., Chen, W., Peng, G., Matsuzaki, J., & Wang, R.-F. (2008) · Proceedings of the National Academy of Sciences

T-cell and B-cell ImmunologyPsoriasis: Treatment and Pathogenesis

Cited by 279

Identification of six new susceptibility loci for invasive epithelial ovarian cancer

EMBRACE, Kuchenbaecker, K. B., Collaborators, G. S., Breast Cancer Family Registry, HEBON, KConFab Investigators, Australian Cancer Study (Ovarian Cancer Investigators), Australian Ovarian Cancer Study Group, the Consortium of Investigators of Modifiers of BRCA1 and BRCA2, Ramus, S. J., et al. (2015) · Nature Genetics

BRCA gene mutations in cancerOvarian cancer diagnosis and treatment

Cited by 250

Elevated Expression of the Serine-Arginine Protein Kinase 1 Gene in Ovarian Cancer and Its Role in Cisplatin Cytotoxicity In Vitro

Odunsi, K., Mhawech-Fauceglia, P., Andrews, C., Beck, A., Amuwo, O., Lele, S., Black, J. D., & Huang, R.-Y. (2012) · PLoS ONE

Ovarian cancer diagnosis and treatmentRNA Research and Splicing

Cited by 53

A prime/boost vaccine platform efficiently identifies CD27 agonism and depletion of myeloid-derived suppressor cells as therapies that rationally combine with checkpoint blockade in ovarian cancer

McGray, A. J. R., Eppolito, C., Miliotto, A., Singel, K. L., Stephenson, K., Lugade, A., Segal, B. H., Keler, T., Webster, G., Lichty, B., et al. (2021) · Cancer Immunology, Immunotherapy

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 12